Mosunetuzumab: A Comprehensive Clinical and Scientific Review of a First-in-Class Bispecific T-Cell Engager for Relapsed/Refractory Follicular Lymphoma

Introduction to Mosunetuzumab: A Novel Bispecific T-Cell Engager in Follicular Lymphoma

The Unmet Need in Relapsed/Refractory Follicular Lymphoma (R/R FL)

Follicular lymphoma (FL) is the second most common subtype of non-Hodgkin lymphoma (NHL) and is generally characterized by an indolent, or slow-growing, clinical course.[1] While it is considered a treatable disease, it is typically incurable with standard therapeutic approaches. The natural history of FL involves a pattern of remission and relapse, where patients often respond well to initial treatments but subsequently experience disease recurrence.[3] With each successive line of therapy, the duration of response and progression-free survival tends to shorten, and the disease may become increasingly refractory to treatment.[3]

A significant unmet clinical need exists for patients with relapsed or refractory (R/R) FL who have progressed after two or more prior lines of systemic therapy. This patient population has often been exposed to, and may be refractory to, standard-of-care agents, including an anti-CD20 monoclonal antibody such as rituximab and an alkylating agent.[5] For these heavily pretreated individuals, therapeutic options are limited, and prognoses are often poor, underscoring the urgent need for novel agents with distinct mechanisms of action and durable efficacy.

Introducing Mosunetuzumab (Lunsumio): A First-in-Class Therapeutic

Mosunetuzumab, marketed under the brand name Lunsumio, represents a significant advancement in the treatment of R/R FL. It is a first-in-class, humanized, bispecific CD20xCD3 T-cell engaging antibody, engineered to redirect the body's own T-cells to target and eliminate malignant B-cells.[10] Regulatory agencies have approved mosunetuzumab specifically for the treatment of adult patients with R/R FL who have received at least two prior lines of systemic therapy, directly addressing the aforementioned unmet need.[6]

Key Therapeutic Advantages: "Off-the-Shelf" and Fixed-Duration Treatment

Mosunetuzumab introduces a paradigm shift in the application of advanced immunotherapy for lymphoma. A key distinction lies in its comparison to autologous chimeric antigen receptor (CAR) T-cell therapies, such as axicabtagene ciloleucel and tisagenlecleucel. Unlike these personalized treatments, which require a complex and lengthy manufacturing process involving the extraction and genetic modification of a patient's own T-cells, mosunetuzumab is an "off-the-shelf" biologic.[5] This means it is a standardized, readily available product that can be administered to patients without the logistical delays and manufacturing hurdles associated with CAR-T therapy.

Furthermore, mosunetuzumab is administered as a fixed-duration regimen. Patients who achieve a complete response can typically complete therapy after eight 21-day cycles (approximately 6 months), while others may continue for up to 17 cycles.[4] This finite treatment course allows for a treatment-free interval for responding patients, a significant advantage over therapies that require continuous administration to maintain efficacy. The ability to administer mosunetuzumab in an outpatient setting further enhances its practicality, reducing the burden on both patients and healthcare infrastructure.[4]

The combination of these features—being an "off-the-shelf" product with a fixed treatment duration and an outpatient administration schedule—fundamentally redefines the accessibility of potent T-cell engaging immunotherapy. CAR-T therapies, despite their profound efficacy, are constrained by significant logistical complexities. The process involves patient apheresis, a multi-week ex-vivo cell manufacturing period, and administration exclusively at highly specialized academic centers equipped to manage potentially severe toxicities like high-grade cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).[5] These requirements create substantial geographic, logistical, and financial barriers, limiting access for a large proportion of otherwise eligible patients.

Mosunetuzumab effectively circumvents these obstacles. As a biotechnologically produced antibody, it is manufactured, stored, and distributed through conventional pharmaceutical channels.[20] Its safety profile, characterized by manageable and predominantly low-grade CRS when administered with a step-up dosing schedule, permits its use in the outpatient setting, including community practice centers.[4] The ongoing MorningSun study is specifically designed to validate the feasibility and safety of this approach in community-based settings, which represent the primary site of cancer care for most patients.[26] Therefore, the primary impact of mosunetuzumab extends beyond its clinical efficacy; it fundamentally alters the treatment landscape by democratizing access to powerful T-cell redirection. This innovation addresses a critical unmet need related not just to drug efficacy, but to healthcare system capacity, patient convenience, and equity of access to advanced cancer therapies.

Table 1: Key Properties of Mosunetuzumab

Property	Detail	Source(s)
Generic Name	Mosunetuzumab (mosunetuzumab-axgb)	10
Brand Name	Lunsumio	10
DrugBank ID	DB15434	10
CAS Number	1905409-39-3	27
Type	Biotech, Protein-Based Therapy	20
Class	Bispecific CD20-directed CD3 T-cell engager	7
Developer/Manufacturer	Genentech (a member of the Roche Group)	10
Indication	Relapsed or refractory follicular lymphoma (R/R FL) after ≥2 prior systemic therapies	10

Molecular Profile and Advanced Mechanism of Action

Structural Characteristics

Mosunetuzumab is a full-length, fully humanized Immunoglobulin G1 (IgG1) bispecific antibody, produced using recombinant DNA technology in Chinese Hamster Ovary (CHO) cells.[15] It possesses a molecular weight of approximately 146.3 kDa and a chemical formula of

C6515​H10031​N1725​O2025​S43​.[10]

A critical aspect of its design is the use of "knobs-into-holes" engineering. This protein engineering technology facilitates the heterodimerization of two distinct heavy chains, ensuring the correct assembly of the bispecific antibody with one arm targeting CD20 and the other targeting CD3, while maintaining the overall stable IgG1 architecture.[15] This structure is fundamental to its manufacturability and contributes to its favorable pharmacokinetic profile, including a long serum half-life, which contrasts with smaller bispecific T-cell engager (BiTE) constructs that often require continuous infusion.[15]

Furthermore, the Fc region of the mosunetuzumab IgG1 backbone is engineered with a specific mutation (N297G) that results in an aglycosylated, or non-sugar-containing, Fc domain.[37] This modification effectively mutes Fc-mediated effector functions, such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), by preventing binding to Fcγ receptors and the C1q component of complement.[36] This intentional silencing of Fc activity focuses the antibody's therapeutic action exclusively on its primary mechanism: the redirection of T-cell cytotoxicity.

Dual-Targeting Mechanism: Bridging T-Cells and B-Cells

The therapeutic innovation of mosunetuzumab lies in its bispecificity, enabling it to simultaneously engage two different antigens on two distinct cell types.

• CD20 Binding Arm: One antigen-binding fragment (Fab) of the antibody is designed to recognize and bind to the CD20 antigen.[5] CD20 is a well-established therapeutic target in B-cell malignancies, as it is a transmembrane protein expressed on the surface of the vast majority of normal and malignant B-lymphocytes, from the pre-B cell stage through to mature B-cells, but is absent on hematopoietic stem cells and terminally differentiated plasma cells.[14] The CD20-binding domain of mosunetuzumab is derived from the 2H7 clone, the same clone used for the anti-CD20 antibody rituximab.[38] However, a key structural difference is that mosunetuzumab possesses only a single binding site for CD20, whereas conventional monoclonal antibodies like rituximab are bivalent.[36]
• CD3 Binding Arm: The second Fab arm is engineered to bind with high affinity to the CD3 epsilon (CD3ε) chain, an invariant component of the T-cell receptor (TCR) complex found on the surface of nearly all cytotoxic and helper T-cells.[5]

Formation of the Cytolytic Synapse and T-Cell Activation

Mosunetuzumab functions as a conditional agonist, meaning its biological activity is contingent upon the simultaneous engagement of both its targets.[5] When mosunetuzumab binds to a CD20-expressing B-cell and a CD3-expressing T-cell, it acts as a molecular bridge, forcing the two cells into close proximity and creating a transient, artificial structure known as a cytolytic or immunological synapse.[15]

This physical linkage triggers the activation of the T-cell. Crucially, this activation occurs independently of the T-cell's native antigen specificity, which is normally dictated by the interaction of its TCR with a specific peptide presented by a major histocompatibility complex (MHC) molecule on an antigen-presenting cell. Mosunetuzumab effectively bypasses this requirement, reprogramming any nearby T-cell to recognize and attack the CD20-positive B-cell.[15]

Downstream Cytotoxic Cascade

Once the cytolytic synapse is formed and the T-cell is activated via CD3 engagement, a potent cytotoxic cascade is initiated.[15] This process involves several key steps:

1. T-Cell Signaling and Proliferation: The cross-linking of the TCR complex activates intracellular signaling pathways, including the nuclear factor of activated T-cells (NFAT), nuclear factor kappa B (NF-κB), and activator protein-1 (AP-1) pathways. This signaling cascade promotes T-cell proliferation, differentiation into effector cells, and the production and secretion of pro-inflammatory cytokines such as interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α).[15]
2. Directed Cytotoxicity: The activated cytotoxic T-cell releases the contents of its lytic granules—primarily perforin and granzymes—directly into the synaptic cleft.[15]
3. Target Cell Lysis: Perforin molecules polymerize to form pores in the plasma membrane of the target B-cell. These pores allow granzymes, which are serine proteases, to enter the B-cell's cytoplasm. Once inside, granzymes initiate a caspase cascade that leads to apoptosis, or programmed cell death, resulting in the efficient and targeted elimination of the malignant B-cell.[15]

This mechanism of action is fundamentally different from that of conventional anti-CD20 antibodies like rituximab, which primarily rely on host-dependent effector mechanisms such as ADCC and CDC. Patients with R/R FL are often refractory to rituximab, potentially due to downregulation of these pathways or other resistance mechanisms. By directly co-opting the potent and direct killing machinery of T-cells, mosunetuzumab provides a novel therapeutic strategy that can circumvent this resistance.[5]

However, the very potency of this mechanism is a double-edged sword. The powerful, non-specific activation of T-cells, which is the key to its efficacy, is also the direct driver of its principal toxicities: cytokine release syndrome and neurotoxicity.[17] This creates a delicate therapeutic balance. The entire clinical administration protocol for mosunetuzumab—including the initial step-up dosing, mandatory premedication, and detailed adverse event management guidelines—is a carefully engineered framework designed to navigate this balance. It aims to harness the full cytotoxic potential of T-cell redirection while mitigating the predictable and potentially severe inflammatory consequences of that same activation. This highlights a core tenet of modern immunotherapy: successful treatment often depends as much on managing the induced immune response as it does on targeting the cancer itself.

Clinical Pharmacology: Pharmacokinetics and Pharmacodynamics

Pharmacokinetics (PK)

The pharmacokinetic profile of mosunetuzumab describes its movement into, through, and out of the body. It has been characterized in both healthy subjects and patients with hematologic malignancies.

• Administration and Absorption: Mosunetuzumab is administered via intravenous (IV) infusion. Pharmacokinetic studies have demonstrated that its exposure, as measured by area under the curve (AUC), is approximately dose-proportional across a range of 0.05 mg to 60 mg.[20] Following infusion, serum concentrations peak at the end of the infusion and subsequently decline in a bi-exponential manner.[5] A subcutaneous formulation is also under investigation, which has shown a slower absorption rate but high bioavailability (>75%) in clinical trials.[20]
• Distribution: The drug exhibits extravascular distribution.[19] The estimated central volume of distribution (Vd) is approximately 5.49 L.[5] This value is consistent with the volume of plasma, indicating that the antibody is primarily confined to the vascular compartment, a typical characteristic for large protein therapeutics like monoclonal antibodies.
• Metabolism: As a large protein, mosunetuzumab is not metabolized by cytochrome P450 (CYP) enzymes. Instead, it is expected to undergo degradation into smaller peptides and constituent amino acids through general intracellular catabolism pathways, which occur throughout the body.[5] Consequently, its elimination is not expected to be significantly influenced by hepatic or renal impairment.[5]
• Elimination and Half-Life: The elimination of mosunetuzumab is characterized by time-dependent clearance, a phenomenon indicative of target-mediated drug disposition (TMDD). The drug's clearance is faster at the beginning of treatment when the target (CD20-expressing B-cells) is abundant and slows as the target cells are depleted. The baseline clearance (CLbase) is approximately 0.584 L/day, which decreases to a steady-state plateau clearance (CLss) of approximately 1.08 L/day.[5] The terminal elimination half-life ( t1/2​) is approximately 16.1 days, which supports the 21-day cycle dosing interval.[5] An apparent half-life ranging from 6 to 11 days has also been reported.[5] Steady-state serum concentrations are typically reached by the fourth treatment cycle (approximately day 84).[5] No drug accumulation was observed after consecutive daily doses in early studies.[19]

Pharmacodynamics (PD)

The pharmacodynamic effects of mosunetuzumab describe the biochemical and physiological effects of the drug on the body, which are directly linked to its mechanism of action.

• T-Cell Activation: Pharmacodynamic evidence of T-cell activation occurs rapidly, observed within hours of the first infusion, even at low, sub-efficacious doses. This is characterized by a transient, dose-dependent decrease in circulating peripheral T-lymphocytes, which is attributed to their margination and trafficking into tissues. This is followed by a recovery of T-cell counts, typically by 72 hours post-infusion. Concurrently, there is a measurable upregulation of T-cell activation markers, such as CD69, on both CD4+ and CD8+ T-cell subsets.[35]
• Cytokine Release: Consistent with T-cell activation, a transient increase in circulating pro-inflammatory cytokines is a key pharmacodynamic effect. Levels of cytokines such as IL-6, IL-2, IFN-γ, and TNF-α peak within the first 24 hours following the Cycle 1, Day 1 infusion. The kinetics and magnitude of the IL-6 increase, in particular, have been shown to correlate with the clinical onset and severity of cytokine release syndrome (CRS).[15] The step-up dosing schedule was specifically designed to temper this initial cytokine surge.[15]
• B-Cell Depletion and Recovery: Mosunetuzumab induces rapid, profound, and sustained depletion of circulating CD20-positive B-cells. This on-target effect is observed immediately after the first dose and is maintained throughout the treatment period.[15] B-cell counts are typically reduced to levels below 0.07 x 109/L.[20] The depletion of normal B-cells is a long-lasting effect. Data from the pivotal GO29781 study showed that after completion of 8 cycles of therapy, the median time to recovery of peripheral CD19+ B-cells to baseline levels or above was 18.4 months (95% CI, 12.8–25.0).[4] This extended period of B-cell aplasia is a critical consideration for monitoring long-term immune function and infection risk.
• Hypogammaglobulinemia: A direct consequence of prolonged B-cell depletion is hypogammaglobulinemia, or a reduction in serum immunoglobulin levels. This is an expected on-target pharmacodynamic effect, with IgG levels potentially falling below 500 mg/dL.[20] This reduction can increase a patient's susceptibility to infections and may require monitoring and, in some cases, immunoglobulin replacement therapy.

Table 2: Summary of Key Pharmacokinetic Parameters for Mosunetuzumab

Parameter	Value	Source(s)
Route of Administration	Intravenous (IV) Infusion	7
Central Volume of Distribution (Vd​)	~5.49 L	5
Baseline Clearance (CLbase​)	~0.584 L/day	5
Steady-State Clearance (CLss​)	~1.08 L/day	5
Terminal Half-Life (t1/2​)	~16.1 days	5
Time to Steady State	~Cycle 4 (Day 84)	5
Metabolism Pathway	Intracellular catabolism	5

Pivotal Clinical Evidence: The GO29781 Study in R/R Follicular Lymphoma

The regulatory approvals of mosunetuzumab were primarily based on the robust efficacy and manageable safety data from the pivotal GO29781 study, a multicenter, open-label, single-arm Phase I/II clinical trial (NCT02500407).[1] The key efficacy analysis was conducted on a cohort of 90 patients with R/R FL who were enrolled in the Phase II expansion portion of the study.[7]

Patient Population

The study enrolled a heavily pretreated and high-risk patient population, reflective of the real-world challenges in this setting. Key eligibility criteria included adult patients with histologically confirmed R/R FL (Grades 1-3a) who had received at least two prior lines of systemic therapy, which must have included at least one anti-CD20 antibody and one alkylating agent.[7]

The baseline characteristics of the 90-patient efficacy cohort highlight the advanced nature of their disease [46]:

• Prior Therapies: Patients had received a median of 3 prior lines of therapy (range, 2-10).
• Refractory Disease: A high proportion of patients were refractory to previous treatments: 69% were refractory to their last prior therapy, 79% were refractory to any prior anti-CD20 therapy, and 53% were double-refractory to both an anti-CD20 monoclonal antibody and an alkylating agent.
• High-Risk Features: 52% of patients had Progression of Disease within 24 months (POD24) of their first-line therapy, a well-established marker of poor prognosis in FL. Furthermore, 21% had undergone a prior autologous stem cell transplant.[46]

Efficacy Results

The primary efficacy endpoint of the study was the complete response (CR) rate, as determined by an independent review facility (IRF) according to the 2007 Cheson criteria.[4] The results, with extended follow-up of approximately three years, demonstrated high and remarkably durable responses.

• Response Rates: Mosunetuzumab achieved a high rate of deep responses in this difficult-to-treat population.
• Objective Response Rate (ORR): The ORR, which includes both complete and partial responses, was consistently reported at 78-80%.[1]
• Complete Response (CR) Rate: The investigator-assessed CR rate was 60% (95% CI, 49.1-70.2).[1] This rate was statistically superior to a pre-specified historical control CR rate of 14% derived from a study of copanlisib, a PI3K inhibitor, in a similar patient population ( P<0.0001).[3]
• Durability of Response: A key finding from the long-term follow-up was the impressive durability of the responses.
• Median Duration of Response (DOR): Among the 70 patients who responded to treatment, the median DOR was 35.9 months (95% CI, 20.7 to not estimable).[4]
• Median Duration of Complete Response (DOCR): For the 54 patients who achieved a CR, the median DOCR was not reached after a median follow-up of 37.4 months (95% CI, 33.0 to not estimable). The Kaplan-Meier estimated 30-month remission rate for these complete responders was 72.4% (95% CI, 59.2-85.6), indicating that the majority of complete remissions were long-lasting.[4]
• Survival Outcomes: The survival data further support the clinical benefit of mosunetuzumab.
• Median Progression-Free Survival (PFS): The median PFS for the entire cohort was 24.0 months (95% CI, 12.0 to not estimable).[4]
• Median Overall Survival (OS): The median OS was not reached. The estimated OS rate at 36 months was 82.4% (95% CI, 73.8-91.0), a highly encouraging result in this advanced disease setting.[4]
• Response Kinetics: Responses to mosunetuzumab were observed relatively quickly. The median time to first response (either partial or complete) was 1.4 months, and the median time to first complete response was 3.0 months.[4]

Table 3: Efficacy Outcomes from the Pivotal GO29781 Study in R/R Follicular Lymphoma (Median Follow-up ~3 years)

Efficacy Endpoint	Result (Value and 95% Confidence Interval)	Source(s)
Objective Response Rate (ORR)	77.8% (67.8–85.9)	4
Complete Response (CR) Rate	60.0% (49.1–70.2)	4
Median Duration of Response (DOR)	35.9 months (20.7–NE)	4
Median Duration of CR (DOCR)	Not Reached (33.0–NE)	4
30-Month CR Rate (in CR patients)	72.4% (59.2–85.6)	4
Median Progression-Free Survival (PFS)	24.0 months (12.0–NE)	4
36-Month Overall Survival (OS) Rate	82.4% (73.8–91.0)	4
NE = Not Estimable

Comprehensive Safety and Tolerability Profile

The safety profile of mosunetuzumab has been characterized in a pooled population of 218 patients with hematologic malignancies who received the recommended dosing regimen. The adverse events are largely mechanism-based and predictable, with specific management strategies outlined in the prescribing information.

BOXED WARNING: Cytokine Release Syndrome (CRS)

Mosunetuzumab carries a Boxed Warning for serious or life-threatening CRS, which is the most common and clinically significant toxicity associated with the drug.[7]

• Incidence: CRS of any grade occurred in 39% to 44% of patients across clinical trials.[6]
• Severity and Grading: The majority of CRS events were of low grade. In the pooled safety population, Grade 1 CRS was reported in 28% and Grade 2 in 15% of patients. Severe events were infrequent, with Grade 3 CRS occurring in 2% and Grade 4 in 0.5% of patients.[7] Recurrent CRS was observed in 11% of patients.[17]
• Timing and Manifestations: CRS events occurred predominantly during Cycle 1 of treatment, with distinct peaks following the initial 1 mg dose on Day 1 (15% incidence) and the first 60 mg dose on Day 15 (33% incidence).[17] The median time to onset from the start of infusion was rapid, typically 3 to 5 hours, and the median duration of events was 3 days.[6] Common clinical manifestations include pyrexia (fever), chills, hypotension, tachycardia, and headache.[41]

Other Key Warnings and Precautions

• Neurologic Toxicity: Neurologic adverse events of any grade were reported in 39% of patients, with Grade 3 toxicity occurring in 3%.[7] This category includes Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), a specific neurotoxicity syndrome linked to T-cell engaging therapies. ICANS was reported in approximately 1-2% of patients and was mostly Grade 1 or 2.[7] Clinical signs can range from headache, dizziness, and confusion to more severe symptoms like seizures or loss of consciousness.[57]
• Serious Infections: Due to its on-target effect of B-cell depletion and subsequent hypogammaglobulinemia, mosunetuzumab can increase the risk of serious infections. In clinical trials, serious infections occurred in 17% of patients, with 14% experiencing Grade 3 or 4 infections. Fatal infections were reported in 0.9% of patients. Commonly reported serious infections included pneumonia, bacteremia, sepsis, and opportunistic infections.[5]
• Cytopenias: Treatment with mosunetuzumab can cause serious or severe cytopenias (low blood cell counts). Grade 3 or 4 laboratory abnormalities were common in the safety population, including decreased lymphocytes (98%), decreased neutrophils (neutropenia, 38%), decreased hemoglobin (anemia, 19%), and decreased platelets (thrombocytopenia, 12%).[7]
• Tumor Flare: Tumor flare, characterized by localized pain and swelling at tumor sites or new/worsening pleural effusions, was reported in 4% of patients. This phenomenon is thought to be caused by the influx of activated T-cells into the tumor microenvironment and is generally transient.[5]

Common Adverse Reactions

In the pooled safety population, the most frequently reported adverse reactions (occurring in ≥20% of patients) were cytokine release syndrome, fatigue, rash, pyrexia, and headache.[6]

Use in Specific Populations

• Pregnancy and Lactation: Based on its mechanism of action and potential for B-cell depletion in a developing fetus, mosunetuzumab may cause fetal harm. Therefore, it is not recommended for use during pregnancy. Females of reproductive potential should be advised to use effective contraception during treatment and for 3 months after the final dose.[17] Similarly, breastfeeding is not recommended during treatment and for 3 months after the last dose due to the potential for the drug to be present in breast milk and cause serious adverse reactions in a nursing infant.[5]

Table 4: Incidence of Key Adverse Reactions in the Pooled Safety Population (N=218)

Adverse Reaction	All Grades (%)	Grade 3-4 (%)	Source(s)
Cytokine Release Syndrome (CRS)	39	2.5 (Grade 3: 2%, Grade 4: 0.5%)	7
Neurologic Toxicity	39	3	7
including ICANS	1	<1	7
Serious Infections	17	14	7
Tumor Flare	4	<1	7
Fatigue	≥20	N/A	7
Rash	≥20	N/A	7
Pyrexia	≥20	N/A	7
Headache	≥20	N/A	7

Dosing, Administration, and Clinical Management

The administration of mosunetuzumab requires strict adherence to a specific dosing schedule and premedication protocol to ensure both safety and efficacy. Management of potential adverse events, particularly CRS and ICANS, is a critical component of its clinical use.

Recommended Dosing Schedule

Mosunetuzumab is administered intravenously in 21-day cycles. A key feature of the regimen is the step-up dosing schedule implemented during the first cycle, which is designed to mitigate the risk and severity of CRS.[7]

• Cycle 1:
• Day 1: 1 mg
• Day 8: 2 mg
• Day 15: 60 mg
• Cycle 2:
• Day 1: 60 mg
• Cycle 3 and Subsequent Cycles:
• Day 1: 30 mg

Duration of Therapy

The total duration of mosunetuzumab treatment is response-adapted and finite:

• Patients receive treatment for a minimum of 8 cycles.
• Those who achieve a complete response (CR) by the end of Cycle 8 should discontinue therapy.
• Patients who achieve a partial response (PR) or have stable disease (SD) at the end of Cycle 8 should continue treatment for an additional 9 cycles, for a total of up to 17 cycles, unless they experience disease progression or unacceptable toxicity.[3]

Premedication Protocol

To reduce the incidence and severity of infusion-related reactions and CRS, a mandatory premedication protocol is required for the initial cycles of therapy.[4]

• Cycles 1 and 2: All patients must receive premedication.
• Cycles 3+: Premedication is required for patients who experienced any grade of CRS with the previous dose.
• The standard premedication regimen consists of:
• Corticosteroid: Dexamethasone 20 mg intravenously (or an equivalent corticosteroid like methylprednisolone 80 mg IV), to be completed at least 1 hour prior to the mosunetuzumab infusion.
• Antihistamine: Diphenhydramine 50-100 mg orally or intravenously (or an equivalent antihistamine), to be administered at least 30 minutes prior to infusion.
• Antipyretic: Acetaminophen 500-1000 mg orally, to be administered at least 30 minutes prior to infusion.

Management of Adverse Events

The prescribing information provides detailed, grade-based management guidelines for the most significant toxicities.

• Cytokine Release Syndrome (CRS): Management is based on the American Society for Transplant and Cellular Therapy (ASTCT) consensus grading. Actions range from temporarily interrupting the infusion for Grade 1 events to permanent discontinuation for Grade 4 events. The use of supportive care, including antipyretics, IV fluids, oxygen, and specific anti-cytokine therapy with tocilizumab and/or corticosteroids, is guided by the severity of the reaction.[17]
• Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS): Management is also grade-based. At the first sign of neurologic toxicity, the infusion should be withheld, and a neurology evaluation should be considered. Management may include supportive care, corticosteroids, and anti-seizure prophylaxis. Severe (Grade 4) or recurrent Grade 3 ICANS necessitates permanent discontinuation of the drug.[17]

Administration Details

• Mosunetuzumab should be administered as an IV infusion through a dedicated line. It should not be administered as an IV push or bolus.
• The infusion line should be flushed with saline if it is also used for other medications.
• An in-line filter should not be used for administration, although drip chamber filters are permissible.
• The infusion duration is a minimum of 4 hours for the initial doses in Cycle 1. If these infusions are well-tolerated, the duration for subsequent higher-dose infusions can be shortened to 2 hours.[19]
• Treatment should only be administered by a qualified healthcare professional in a setting with appropriate medical support to manage potential severe reactions.[19]

Table 5: Recommended Dosing and Premedication Schedule for Mosunetuzumab

Cycle	Day	Mosunetuzumab Dose	Infusion Duration	Premedication
Cycle 1	Day 1	1 mg	Minimum 4 hours	Required: Corticosteroid, Antihistamine, Antipyretic
	Day 8	2 mg	Minimum 4 hours	Required: Corticosteroid, Antihistamine, Antipyretic
	Day 15	60 mg	Minimum 4 hours	Required: Corticosteroid, Antihistamine, Antipyretic
Cycle 2	Day 1	60 mg	2 hours (if C1 tolerated)	Required: Corticosteroid, Antihistamine, Antipyretic
Cycles 3+	Day 1	30 mg	2 hours (if prior infusions tolerated)	As needed: Required if CRS with previous dose
(Source: 7)

Table 6: Management Guidelines for Cytokine Release Syndrome (CRS)

Grade	Clinical Manifestations	Management Actions
Grade 1	Fever ≥38∘C	Withhold infusion. Manage symptoms. Restart at same rate if resolved. Ensure resolution for ≥72 hrs before next dose.
Grade 2	Fever with hypotension (not requiring vasopressors) and/or hypoxia (requiring low-flow oxygen)	Withhold infusion. Manage symptoms. Restart at 50% rate if resolved. If refractory, consider tocilizumab/dexamethasone. For next dose, maximize premedication and consider 50% infusion rate. Manage recurrent Grade 2 as Grade 3.
Grade 3	Fever with hypotension (requiring a vasopressor) and/or hypoxia (requiring high-flow oxygen)	Withhold LUNSUMIO. Provide supportive care (may include intensive care). Administer tocilizumab and/or corticosteroids. For next dose, hospitalize patient and infuse at 50% rate.
Grade 4	Fever with hypotension (requiring multiple vasopressors) and/or hypoxia (requiring mechanical ventilation)	Permanently discontinue LUNSUMIO. Provide supportive care including intensive care. Administer tocilizumab and corticosteroids.
(Source: 17)

Table 7: Management Guidelines for Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

Grade	Clinical Manifestations (ICE Score)	Management Actions
Grade 1	ICE Score 7-9; depressed level of consciousness but awakens spontaneously	Withhold LUNSUMIO until symptoms improve to baseline. Provide supportive therapy and consider neurology evaluation.
Grade 2	ICE Score 3-6; awakens to voice	Withhold LUNSUMIO. Provide supportive therapy. Administer dexamethasone until improvement, then taper. Consider neurology evaluation.
Grade 3	ICE Score 0-2; awakens to tactile stimulus; any clinical seizure	Withhold LUNSUMIO. Provide supportive/intensive care. Administer dexamethasone. Consider neurology evaluation. Permanently discontinue for recurrent Grade 3.
Grade 4	ICE Score 0; patient unarousable; life-threatening seizure; diffuse cerebral edema	Permanently discontinue LUNSUMIO. Provide intensive care. Administer high-dose corticosteroids (e.g., methylprednisolone).
(Source: 17)

Regulatory Status and Clinical Practice Guidelines

Regulatory Approvals

Mosunetuzumab has received regulatory approval from major health authorities based on the strength of the data from the GO29781 trial.

• U.S. Food and Drug Administration (FDA): On December 22, 2022, the FDA granted Accelerated Approval to mosunetuzumab-axgb (Lunsumio) for the treatment of adult patients with R/R FL who have received two or more prior lines of systemic therapy.[6] This approval pathway is used for drugs that treat serious conditions and fill an unmet medical need based on a surrogate endpoint—in this case, response rate—that is reasonably likely to predict clinical benefit. Continued approval for this indication is contingent upon verification and description of clinical benefit in a confirmatory trial.[6] The FDA had previously granted mosunetuzumab both Breakthrough Therapy and Orphan Drug designations for this indication, highlighting its potential significance.[10]
• European Medicines Agency (EMA): On June 8, 2022, the European Commission granted a Conditional Marketing Authorisation for mosunetuzumab for the same indication.[4] This decision followed a positive opinion adopted by the Committee for Medicinal Products for Human Use (CHMP) in April 2022.[10] Similar to accelerated approval, conditional authorisation is granted for medicines that address an unmet need, where the benefit of immediate availability outweighs the risk of less comprehensive data, and is subject to the submission of further evidence from ongoing studies.

Clinical Practice Guidelines

The rapid integration of mosunetuzumab into clinical practice is reflected in its inclusion in major oncology treatment guidelines.

• National Comprehensive Cancer Network (NCCN) Guidelines: The NCCN, a leading authority on cancer care standards in the United States, has incorporated mosunetuzumab into its guidelines for B-Cell Lymphomas. For third-line and subsequent therapy in classic follicular lymphoma, mosunetuzumab-axgb is listed as a Category 2A, Preferred Regimen.[31]
• American Society of Clinical Oncology (ASCO) and other Guidelines: While specific, detailed ASCO guidelines for mosunetuzumab were not available in the reviewed materials, its FDA approval and prominent NCCN recommendation firmly establish it as a standard-of-care option in the third-line and beyond setting for R/R FL.[2] It is anticipated that future updates from ASCO and the European Society for Medical Oncology (ESMO) will formally incorporate mosunetuzumab in a similar capacity.

The designation of mosunetuzumab as a "Preferred Regimen" by the NCCN carries significant clinical weight. The NCCN framework categorizes recommendations based on both the level of evidence and the degree of consensus among the expert panel, and also assigns a level of preference.[31] A "Category 2A" recommendation indicates that there is uniform NCCN consensus that the intervention is appropriate, based on lower-level evidence (such as the single-arm Phase II trial that supported mosunetuzumab's approval), which is a standard classification for drugs receiving accelerated approval.[31]

However, the "Preferred" designation is a distinct and higher endorsement. It signifies that, among the various appropriate options for this clinical scenario, the expert panel considers this regimen to be superior based on a composite assessment of efficacy, safety, and the quality of evidence.[31] In the heavily pretreated R/R FL setting, alternative therapies include various chemotherapy combinations, PI3K inhibitors (which carry a significant toxicity burden), lenalidomide-based regimens, and CAR-T cell therapy. The NCCN panel likely weighed the high, durable complete response rates and the manageable, predictable safety profile of mosunetuzumab against these alternatives and concluded that it represents a superior choice for many patients. For a practicing oncologist, this "Preferred" status is a crucial directive, signaling that mosunetuzumab should be a primary consideration for eligible patients, not merely a secondary or tertiary option. This endorsement is likely to influence both clinical decision-making and reimbursement policies from payers.

Therapeutic Context and Future Directions

Comparison with CAR-T Cell Therapies

A central consideration for clinicians is the positioning of mosunetuzumab relative to CAR-T cell therapies, which are also approved for R/R FL.

• Efficacy: While direct head-to-head trials are lacking, cross-trial comparisons and cost-effectiveness models provide some context. CAR-T therapies like axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) may demonstrate slightly higher overall and complete response rates in some analyses. However, mosunetuzumab achieves very high and durable response rates in its own right, with a 60% CR rate and a median DOR of nearly three years in responders.[4]
• Safety: Mosunetuzumab generally exhibits a more favorable and manageable safety profile. The rates of severe (Grade ≥3) CRS and ICANS are substantially lower with mosunetuzumab compared to those reported for axi-cel and tisa-cel in their pivotal trials. For instance, Grade ≥3 CRS occurs in ~2% of patients with mosunetuzumab, compared to 6% with axi-cel, while Grade ≥3 ICANS is rare with mosunetuzumab (<1%) but occurs in 15% of patients with axi-cel.[22]
• Logistics and Cost-Effectiveness: This is where mosunetuzumab holds a distinct advantage. Its "off-the-shelf" availability eliminates the manufacturing delays and complex logistics inherent to CAR-T therapy, allowing for more timely treatment initiation.[22] Economic models from a US payer perspective consistently suggest that mosunetuzumab is a more cost-effective strategy than both axi-cel and tisa-cel. This is driven by lower direct acquisition and administration costs, as well as significantly reduced costs associated with hospitalization and the management of severe adverse events.[24]

Sequencing and Resistance

The emergence of multiple T-cell engaging therapies raises questions about optimal sequencing.

• Post-CAR-T Efficacy: Mosunetuzumab has demonstrated clinical activity in patients whose disease has relapsed or become refractory after prior CAR-T therapy, establishing it as a viable subsequent treatment option.[19] Emerging data suggest that a longer time interval between CAR-T infusion and the initiation of mosunetuzumab may be associated with a higher probability of response.[69]
• Mechanisms of Resistance: Understanding resistance is key to optimizing treatment. Loss of the target antigen, CD20, through reduced transcription or the acquisition of truncating mutations in the MS4A1 gene, has been identified as a primary mechanism of acquired resistance to mosunetuzumab. This finding has important implications for patient selection and may necessitate re-biopsy at the time of progression to assess CD20 status before considering another anti-CD20 agent.[14]

Ongoing Research and Future Perspectives

The development program for mosunetuzumab is robust and continues to expand.

• New Indications: Clinical trials are actively evaluating its efficacy in other B-cell malignancies, including aggressive lymphomas like Diffuse Large B-cell Lymphoma (DLBCL) and indolent diseases like Chronic Lymphocytic Leukemia (CLL).[26]
• Combination Therapies: Numerous studies are exploring mosunetuzumab in combination with other novel agents, such as the antibody-drug conjugate polatuzumab vedotin, the BTK inhibitor pirtobrutinib, and the immunomodulatory drug lenalidomide, with the goal of improving response rates and overcoming resistance.[31]
• Subcutaneous Formulation: A subcutaneous formulation of mosunetuzumab is in late-stage clinical development. This formulation could offer greater convenience, reduce infusion-related burdens, and potentially further improve the safety profile, particularly regarding infusion-related reactions.[26]

Table 8: Comparative Overview: Mosunetuzumab vs. CAR-T Therapies for R/R Follicular Lymphoma

Feature	Mosunetuzumab	CAR-T Therapies (Axi-cel, Tisa-cel)
Mechanism	Bispecific antibody engages endogenous T-cells to target CD20+ B-cells	Genetically modified autologous T-cells express a receptor to target CD19+ B-cells
Efficacy (CR Rate)	~60%	~70-80%
Key Toxicities	Lower rates of severe CRS (~2%) and ICANS (<1%)	Higher rates of severe CRS (~6%) and ICANS (~15% for axi-cel)
Administration	Intravenous infusion in outpatient setting	Single intravenous infusion, requires hospitalization
Availability	"Off-the-shelf," readily available	Patient-specific manufacturing, weeks-long delay
Cost Profile	Lower overall treatment and AE management costs; considered more cost-effective	High upfront drug cost, plus significant costs for hospitalization and AE management
(Source: 5)

Conclusion and Expert Recommendations

Mosunetuzumab represents a landmark achievement in the treatment of relapsed/refractory follicular lymphoma. It provides a highly effective, chemotherapy-free therapeutic option that can induce deep and, critically, durable remissions in a heavily pretreated patient population with limited alternatives. Its unique "off-the-shelf," fixed-duration, and outpatient-compatible nature fundamentally changes the accessibility of potent T-cell engaging immunotherapy, moving it from the exclusive domain of specialized transplant centers into broader clinical practice.

The primary toxicities of mosunetuzumab, namely cytokine release syndrome and neurologic toxicity, are direct, predictable consequences of its powerful T-cell activating mechanism. However, extensive clinical investigation has demonstrated that these risks are manageable for the vast majority of patients through the implementation of a carefully designed step-up dosing schedule, mandatory premedication, and clear, grade-based adverse event management protocols.

Based on the comprehensive evidence, the following recommendations are put forth:

• For Clinical Practice:
• Mosunetuzumab should be considered a preferred standard-of-care option for adult patients with follicular lymphoma who have relapsed after or are refractory to at least two prior lines of systemic therapy, in accordance with NCCN guidelines.
• Clinicians must ensure strict adherence to the established step-up dosing regimen, premedication protocol, and adverse event management guidelines to maximize patient safety. Proactive education of patients and care teams on the signs of CRS and ICANS is paramount.
• Routine monitoring for on-target effects, including cytopenias and hypogammaglobulinemia, is essential. Prophylactic measures against infection and the use of immunoglobulin replacement should be considered as clinically indicated.
• In the event of disease progression after treatment, a repeat biopsy to confirm CD20 expression is strongly recommended before considering subsequent anti-CD20 therapies.
• For Future Research:
• The most critical areas for future investigation involve the integration of mosunetuzumab into earlier lines of therapy for FL, both as a monotherapy and in combination, to determine if it can improve upon or replace standard chemoimmunotherapy.
• Rational combination strategies aimed at deepening responses and overcoming resistance mechanisms (e.g., combining with agents that modulate the tumor microenvironment or upregulate CD20) are a high priority.
• The long-term efficacy and safety data for the subcutaneous formulation are eagerly awaited, as this could further enhance patient convenience and accessibility.
• As more bispecific antibodies become available, head-to-head comparative trials will be necessary to delineate the optimal agent and sequence for individual patients based on nuanced differences in efficacy and safety.

In summary, mosunetuzumab has successfully established a new and vital therapeutic modality for patients with advanced follicular lymphoma. Its continued development and strategic integration into treatment algorithms hold the promise of further improving outcomes for patients with this and other B-cell malignancies.

Works cited

1. Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma | Haematologica, accessed June 19, 2025, https://haematologica.org/article/view/haematol.2023.283737
2. Mosunetuzumab for the treatment of follicular lymphoma - PubMed, accessed June 19, 2025, https://pubmed.ncbi.nlm.nih.gov/39259182/
3. SMC2542 mosunetuzumab concentrate for solution for infusion (Lunsumio®) Roche Products Ltd - Scottish Medicines Consortium, accessed June 19, 2025, https://scottishmedicines.org.uk/media/7819/mosunetuzumab-lunsumio-final-august-2023-for-website.pdf
4. Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies | Blood, accessed June 19, 2025, https://ashpublications.org/blood/article/145/7/708/525779/Long-term-3-year-follow-up-of-mosunetuzumab-in
5. Mosunetuzumab - PubChem, accessed June 19, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Mosunetuzumab
6. FDA Approves Mosunetuzumab-axgb for Follicular Lymphoma - Blood Cancers Today, accessed June 19, 2025, https://www.bloodcancerstoday.com/post/fda-approves-mosunetuzumab-axgb-for-follicular-lymphoma
7. FDA grants accelerated approval to mosunetuzumab-axgb for relapsed or refractory follicular lymphoma, accessed June 19, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-mosunetuzumab-axgb-relapsed-or-refractory-follicular-lymphoma
8. European Commission Approves Mosunetuzumab for Patients with R/R Follicular Lymphoma - Targeted Oncology, accessed June 19, 2025, https://www.targetedonc.com/view/european-commission-approves-mosunetuzumab-for-patients-with-r-r-follicular-lymphoma
9. Mosunetuzumab Induces Deep Remissions in Patients with Relapsed/Refractory Follicular Lymphoma | Value-Based Cancer Care, accessed June 19, 2025, https://www.valuebasedcancer.com/issues/2022/february-2022-vol-13-no-1-online-only/3130:mosunetuzumab-induces-deep-remissions-in-patients-with-relapsed-refractory-follicular-lymphoma
10. Mosunetuzumab - Wikipedia, accessed June 19, 2025, https://en.wikipedia.org/wiki/Mosunetuzumab
11. www.roche.com, accessed June 19, 2025, https://www.roche.com/solutions/pharma/productid-38f92de6-c8d3-402a-9f1a-32ac9102b74d#:~:text=Roche%20%7C%20Lunsumio%20(mosunetuzumab)
12. Definition of mosunetuzumab-axgb - NCI Drug Dictionary, accessed June 19, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/mosunetuzumab
13. Lunsumio (mosunetuzumab) - Roche, accessed June 19, 2025, https://www.roche.com/solutions/pharma/productid-38f92de6-c8d3-402a-9f1a-32ac9102b74d
14. Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas - American Society of Hematology, accessed June 19, 2025, https://ashpublications.org/blood/article/143/9/822/506503/Loss-of-CD20-expression-as-a-mechanism-of
15. What is the mechanism of action of Mosunetuzumab? - Patsnap Synapse, accessed June 19, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-action-of-mosunetuzumab
16. Approval of Mosunetuzumab Becomes 'Critically Important' First-Line Treatment Option in R/R Follicular Lymphoma, Expert Says - CancerNetwork, accessed June 19, 2025, https://www.cancernetwork.com/view/approval-of-mosunetuzumab-becomes-critically-important-first-line-treatment-option-in-r-r-follicular-lymphoma
17. Lunsumio™ (mosunetuzumab-axgb) - Information for Healthcare Providers - Genentech, accessed June 19, 2025, https://www.gene.com/medical-professionals/medicines/lunsumio
18. FDA Grants Lunsumio Accelerated Approval for Relapsed or Refractory Follicular Lymphoma | Value-Based Cancer Care, accessed June 19, 2025, https://www.valuebasedcancer.com/issues/2023/february-2023-vol-14-no-1/fda-grants-lunsumio-accelerated-approval-for-relapsed-or-refractory-follicular-lymphoma
19. This label may not be the latest approved by FDA. For current ..., accessed June 19, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761263s000lbl.pdf
20. Mosunetuzumab: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed June 19, 2025, https://go.drugbank.com/drugs/DB15434
21. Mosunetuzumab, the First Bispecific Approved for Follicular Lymphoma - Hematology & Oncology - Millennium Medical Publishing, accessed June 19, 2025, https://www.hematologyandoncology.net/archives/october-2023/mosunetuzumab-the-first-bispecific-approved-for-follicular-lymphoma/
22. Mosunetuzumab Appears to Reduce Unmet Needs Associated With CAR T-Cell Therapy for R/R Follicular Lymphoma - CancerNetwork, accessed June 19, 2025, https://www.cancernetwork.com/view/mosunetuzumab-appears-to-reduce-unmet-needs-associated-with-car-t-cell-therapy-for-r-r-follicular-lymphoma
23. LUNSUMIO™ (mosunetuzumab-axgb) Dosing Schedule | HCP, accessed June 19, 2025, https://www.lunsumio-hcp.com/dosing-and-administration/dosing-schedule.html
24. A Cost-Effectiveness Analysis of Mosunetuzumab vs Tisagenlecleucel for Treatment of Third- or Higher-Line (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in Italy - PMC, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12009579/
25. Full article: Cost effectiveness of mosunetuzumab and CAR-T cell therapy in relapsed/refractory follicular lymphoma - Taylor & Francis Online: Peer-reviewed Journals, accessed June 19, 2025, https://www.tandfonline.com/doi/full/10.1080/10428194.2025.2506498?src=exp-la
26. Care Coordination for Mosunetuzumab Therapy in Patients With Follicular Lymphoma in Community Practices: Learnings From the MorningSun Study Investigators - PMC, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12117195/
27. Mosunetuzumab | CAS NO.:1905409-39-3 - GlpBio, accessed June 19, 2025, https://www.glpbio.com/mosunetuzumab.html
28. Mosunetuzumab (BTCT-4465A) | CD20/CD3 Inhibitor - MedchemExpress.com, accessed June 19, 2025, https://www.medchemexpress.com/mosunetuzumab.html
29. Mosunetuzumab (Anti-CD20 & CD3e) CD markers inhibitor - Selleck Chemicals, accessed June 19, 2025, https://www.selleckchem.com/products/mosunetuzumab-anti-cd20-cd3e-.html
30. Lunsumio (mosunetuzumab) dosing, indications, interactions, adverse effects, and more, accessed June 19, 2025, https://reference.medscape.com/drug/lunsumio-mosunetuzumab-4000308
31. Lunsumio (mosunetuzumab-axgb), accessed June 19, 2025, https://hhs.iowa.gov/media/13170/download?inline
32. Mosunetuzumab - Genentech - AdisInsight - Springer, accessed June 19, 2025, https://adisinsight.springer.com/drugs/800042913
33. Lunsumio, INN-mosunetuzumab - European Medicines Agency, accessed June 19, 2025, https://www.ema.europa.eu/en/documents/product-information/lunsumio-epar-product-information_en.pdf
34. Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study - PMC, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8824395/
35. Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling - PubMed Central, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7455723/
36. Anti-Human CD3 x CD20 (Mosunetuzumab) – Fc Muted™ - Leinco Technologies, accessed June 19, 2025, https://www.leinco.com/p/anti-human-cd3-x-cd20-mosunetuzumab-fc-muted/
37. European Commission approves Lunsumio for people with relapsed or refractory follicular lymphoma - The Antibody Society, accessed June 19, 2025, https://www.antibodysociety.org/approvals/european-commission-approves-lunsumio-for-people-with-relapsed-or-refractory-follicular-lymphoma/
38. Two Are Better than One: The Bi-Specific Antibody Mosunetuzumab Reveals an Improved Immune Response of Vγ9Vδ2 T Cells Targeting CD20 in Malignant B Cells in Comparison to the Mono-Specific Antibody Obinutuzumab - MDPI, accessed June 19, 2025, https://www.mdpi.com/1422-0067/26/3/1262
39. Lunsumio® (mosunetuzumab-axgb) | Genentech Prescribing & Product Information, accessed June 19, 2025, https://www.genentech-medinfo.com/our-products/oncology/lunsumio.html
40. Fixed-Duration SC Mosunetuzumab Shows 83% PFS at 1 Year in Untreated HTB Follicular Lymphoma - American Journal of Managed Care, accessed June 19, 2025, https://www.ajmc.com/view/fixed-duration-sc-mosunetuzumab-shows-83-pfs-at-1-year-in-untreated-htb-follicular-lymphoma
41. Mosunetuzumab (Lunsumio®) as monotherapy for the treatment of relapsed or refractory follicular lymphoma (FL), accessed June 19, 2025, https://eprints.aihta.at/1377/1/Oncology%20Fact%20Sheet%20Nr.92_Update.pdf
42. Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma | Blood | American Society of Hematology, accessed June 19, 2025, https://ashpublications.org/blood/article/134/Supplement_1/1585/427252/Pharmacodynamic-Effects-and-Immune-Correlates-of
43. Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11863491/
44. Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies - PubMed, accessed June 19, 2025, https://pubmed.ncbi.nlm.nih.gov/39447094/
45. Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma - PMC, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11215382/
46. Mosunetuzumab Is Effective and Tolerable in Relapsed/Refractory Follicular Lymphoma, accessed June 19, 2025, https://www.cancernetwork.com/view/mosunetuzumab-is-effective-and-tolerable-in-relapsed-refractory-follicular-lymphoma
47. Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study | Journal of Clinical Oncology - ASCO Publications, accessed June 19, 2025, https://ascopubs.org/doi/10.1200/JCO.23.02329
48. Mosunetuzumab Induces Durable Response in patients With R/R Follicular Lymphoma, accessed June 19, 2025, https://www.targetedonc.com/view/mosunetuzumab-induces-durable-response-in-patients-with-r-r-follicular-lymphoma
49. Mosunetuzumab Shows High Response Rates in Relapsed/Refractory Follicular Lymphoma - Oncology Nursing News, accessed June 19, 2025, https://www.oncnursingnews.com/view/mosunetuzumab-shows-high-response-rates-in-relapsed-refractory-follicular-lymphoma
50. EMA Recommends Conditional Approval of Mosunetuzumab for Follicular Lymphoma, accessed June 19, 2025, https://www.bloodcancerstoday.com/post/ema-recommends-conditional-approval-of-mosunetuzumab-for-follicular-lymphoma
51. Mosunetuzumab Approved in Europe for Relapsed/Refractory Follicular Lymphoma, accessed June 19, 2025, https://www.onclive.com/view/mosunetuzumab-approved-in-europe-for-relapsed-refractory-follicular-lymphoma
52. Mosunetuzumab Approaches EU Approval for Relapsed or Refractory Follicular Lymphoma, accessed June 19, 2025, https://www.onclive.com/view/mosunetuzumab-approaches-eu-approval-for-relapsed-or-refractory-follicular-lymphoma
53. Mosunetuzumab Led to Durable Complete Response in Majority of Patients with Lymphoma During Follow-Up Study - Pharmacy Times, accessed June 19, 2025, https://www.pharmacytimes.com/view/mosunetuzumab-led-to-durable-complete-response-in-majority-of-patients-with-lymphoma-during-follow-up-study
54. Drug Trials Snapshot: LUNSUMIO - FDA, accessed June 19, 2025, https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-lunsumio
55. A phase 2 trial of mosunetuzumab with lenalidomide augmentation as first-line therapy for follicular (FL) and marginal zone lymphoma (MZL). - ASCO, accessed June 19, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT406818
56. FDA D.I.S.C.O. Burst Edition: FDA approval of Lunsumio (mosunetuzumab-axgb) for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy, accessed June 19, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-lunsumio-mosunetuzumab-axgb-adult-patients-relapsed-or
57. Downloadable Resources | LUNSUMIO™ (mosunetuzumab-axgb), accessed June 19, 2025, https://www.lunsumio.com/resources/downloads.html
58. Lunsumio 30 mg concentrate for solution for infusion - Summary of Product Characteristics (SmPC) - (emc) | 14121, accessed June 19, 2025, https://www.medicines.org.uk/emc/product/14121/smpc
59. LUNSUMIO™ (mosunetuzumab-axgb) is a prescription medicine for people with follicular lymphoma (FL) whose cancer has come back or did not respond to previous treatment, and who have already received two or more treatments for their cancer., accessed June 19, 2025, https://www.lunsumio.com/
60. Mosunetuzumab (Lunsumio)® RMP Summary - Swissmedic, accessed June 19, 2025, https://www.swissmedic.ch/dam/swissmedic/en/dokumente/marktueberwachung/rmp/mosunetuzumab_lunsumio_rmp-summary.pdf.download.pdf/Mosunetuzumab_Lunsumio%20_RMP%20Summary_V1.pdf
61. Mosunetuzumab receives FDA approval for the treatment of R/R follicular lymphoma, accessed June 19, 2025, https://lymphomahub.com/lym/medical-information/mosunetuzumab-receives-fda-approval-for-the-treatment-of-rr-follicular-lymphoma
62. Resolution, accessed June 19, 2025, https://www.g-ba.de/downloads/39-1464-5769/2022-12-15_AM-RL-XII_Mosunetuzumab_D-825_EN.pdf
63. A Cost-effectiveness Analysis of Mosunetuzumab vs Tisagenlecleucel for | CEOR, accessed June 19, 2025, https://www.dovepress.com/a-cost-effectiveness-analysis-of-mosunetuzumab-vs-tisagenlecleucel-for-peer-reviewed-fulltext-article-CEOR
64. Cost effectiveness of mosunetuzumab and CAR-T cell therapy in relapsed/refractory follicular lymphoma - Larvol Delta, accessed June 19, 2025, https://delta.larvol.com/NewsItem/NewsItemID/c53a84a4-67a4-41bd-a853-5631df009a69/Cost+effectiveness+of+mosunetuzumab+and+CAR-T+cell+therapy+in+relapsed%202frefractory+follicular+lymphoma.
65. Cost effectiveness of mosunetuzumab and CAR-T cell therapy in relapsed/refractory follicular lymphoma - ResearchGate, accessed June 19, 2025, https://www.researchgate.net/publication/392533195_Cost_effectiveness_of_mosunetuzumab_and_CAR-T_cell_therapy_in_relapsedrefractory_follicular_lymphoma?_tp=eyJjb250ZXh0Ijp7InBhZ2UiOiJqb3VybmFsIiwicHJldmlvdXNQYWdlIjpudWxsLCJzdWJQYWdlIjoib3ZlcnZpZXcifX0
66. Cost Effectiveness of Mosunetuzumab and CAR-T Cell Therapy in Relapsed/Refractory Follicular Lymphoma | Blood | American Society of Hematology, accessed June 19, 2025, https://ashpublications.org/blood/article/142/Supplement%201/256/502604/Cost-Effectiveness-of-Mosunetuzumab-and-CAR-T-Cell
67. Mosunetuzumab is Cost-Effective Compared with Alternative Novel Treatment Options in Patients with Third-Line or Later Relapsed/Refractory Follicular Lymphoma Over a Long-Term Horizon in the United States | Blood | American Society of Hematology, accessed June 19, 2025, https://ashpublications.org/blood/article/144/Supplement%201/3648/529190/Mosunetuzumab-is-Cost-Effective-Compared-with
68. Cost-effectiveness of treating relapsed or refractory 3L+ follicular lymphoma with axicabtagene ciloleucel vs mosunetuzumab in the United States - PubMed, accessed June 19, 2025, https://pubmed.ncbi.nlm.nih.gov/38855109/
69. Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas - PMC, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11869845/
70. Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas | Blood Advances | American Society of Hematology, accessed June 19, 2025, https://ashpublications.org/bloodadvances/article/9/4/696/526100/Impact-of-prior-CAR-T-cell-therapy-on
71. Aggressive Non-Hodgkin Lymphoma Recruiting Phase 2 Trials for Mosunetuzumab (DB15434) | DrugBank Online, accessed June 19, 2025, https://go.drugbank.com/indications/DBCOND0030601/clinical_trials/DB15434?phase=2&status=recruiting
72. Relapsed Cancer Recruiting Phase 1 / 2 Trials for Mosunetuzumab (DB15434) - DrugBank, accessed June 19, 2025, https://go.drugbank.com/indications/DBCOND0089699/clinical_trials/DB15434?phase=1%2C2&status=recruiting
73. CAS NO. 1905409-39-3 | Mosunetuzumab | Catalog HY-P99033 | Arctom | Products, accessed June 19, 2025, https://arctomsci.com/AS1020192-1
74. Mosunetuzumab Not Yet Recruiting Phase 2 Trials for Refractory Follicular Lymphoma / Follicular Lymphoma Grade IIIa / Grade 2 Follicular Lymphoma / Grade 1 Follicular Lymphoma / Recurrent Follicular Lymphoma Treatment - DrugBank, accessed June 19, 2025, https://go.drugbank.com/drugs/DB15434/clinical_trials?conditions=DBCOND0080606%2CDBCOND0049078%2CDBCOND0049079%2CDBCOND0041111%2CDBCOND0041114&phase=2&purpose=treatment&status=not_yet_recruiting
75. SWOG 2308: Randomized Phase III Study of Mosunetuzumab Versus Rituximab for Low–Tumor Burden Follicular Lymphoma | JCO Oncology Advances - ASCO Publications, accessed June 19, 2025, https://ascopubs.org/doi/10.1200/OA-25-00037